Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML

Share :
Published: 13 Dec 2021
Views: 349
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA

Prof Nicholas Short speaks to ecancer about a study he presented at the ASH 2021 meeting into the use of the triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukaemia.

He reports that the triplet combination showed a response rate of 69% in the relapsed/refractory population and 100% in the front-line cohort.

Prof Short explains that the study continues to enrol patients and his hope is, if the data holds up, that this could be used more broadly out of clinical trials.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.